Disease Areas

Woman in blue shirt holding a baby and kissing him on the forehead

The potential to transform patient lives drives us at Biogen.

Amyotrophic Lateral Sclerosis (ALS)

For over a decade, Biogen has been committed to advancing ALS research to provide a deeper understanding of all forms of this devastating disease, which currently impacts an estimated 3,000 Canadians1 and 352,000 people worldwide.2,3*

Alzheimer’s Disease and Dementia

Our world-class neurology research and development organization is pushing toward novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease. 

Multiple Sclerosis (MS)

Biogen has pioneered the development of MS treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS. Our ongoing research into neurodegeneration and nerve repair will help produce new therapeutic solutions that may bring us closer to a cure. 

Spinal Muscular Atrophy (SMA)

Biogen is dedicated to enhancing the lives of those with SMA and their families through ongoing research, removing barriers to access and providing support programs. In December 2017, Biogen launched a collaboration with Ionis to identify new therapeutic options — specifically, new antisense oligonucleotide (ASO) candidates, which are designed to treat SMA — for individuals afflicted with the debilitating disease.

  1. About ALS – ALS Society of Canada. Accessed April 5, 2023
  2. Xu 2020. Reference: Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, Zhan S, Wang S. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020 Apr;267(4):944-953
  3. United Nations, World population prospects: The 2010 revision (2022). New York.
    * calculated based on prevalence estimates and applied to the global population